Surveyed U.S. Cardiologists Indicate That They Would Prescribe Cardiome/Merck’s Oral Vernakalant and Gilead/Menarini’s Ran

The Atrial Fibrillation Drug Market Will Undergo Significant Growth, Expanding from $1.3 Billion in 2010 to $8.9 Billion in 2020, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. cardiologists indicate that they would prescribe Cardiome/Merck’s oral vernakalant and Gilead/Menarini’s ranolazine to 13 percent of their atrial fibrillation patients. Additionally, these agents are forecasted to capture a similar patient share of 10 percent in the U.S. by 2020.

“Several components of vernakalant’s mechanism of action could ensure that it yields strong atrial-selective effects, which would reduce the risk of adverse events arising from off-target effects on the ventricles and confer an important competitive advantage over currently available oral antiarrhythmics,” said Decision Resources Analyst Conor Walsh, Ph.D. “Additionally, we expect the uptake of ranolazine will be due to its strong safety profile and clinical data indicating its notable antiarrhythmic efficacy.”

Decision Resources’ analysis of the atrial fibrillation drug market also finds that, based on clinical data and the opinions of interviewed thought leaders, amiodarone (Sanofi-Aventis’s Cordarone, generics) has earned Decision Resources’ proprietary clinical gold-standard status for atrial fibrillation, owing to its strongest clinical profile among key marketed products that control normal sinus rhythm (NSR) in atrial fibrillation. Decision Resources does not expect any therapy in development to replace amiodarone as its proprietary clinical gold standard for atrial fibrillation. While some emerging therapies hold promise, they have efficacy, safety and tolerability, and/or delivery features that prevent them from displacing amiodarone.

Surveyed U.S. cardiologists and managed care organization pharmacy directors agree that the rate of mortality is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in the control of NSR in atrial fibrillation. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage on this attribute over the market’s sales-leading agent, Sanofi’s Multaq. However, perceptions of Multaq’s safety have undoubtedly been affected by a series of concerns raised about the drug in 2011, as only 15 percent of surveyed cardiologists identified it as the safest and best tolerated therapy for atrial fibrillation.

The findings also reveal that the atrial fibrillation drug market will undergo a period of significant, sustained growth, expanding from $1.3 billion in 2010 to $8.9 billion in 2020. The launch and rapid uptake of new oral anticoagulants, atrial-selective antiarrhythmic drugs and the expanding prevalent patient population will be the key drivers of market growth. Additionally, stroke prevention in atrial fibrillation is undergoing a transformation and is the most active area of drug development. A wave of new oral anticoagulants, with clinical profiles superior to that of warfarin (Bristol-Myers Squibb’s Coumadin, Eisai’s Warfarin, generics), will capture 72 percent of the atrial fibrillation drug market by 2020. The leading anticoagulants will be Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban), Bayer/Janssen’s Xarelto (rivaroxaban), and Boehringer Ingelheim’s Pradaxa (dabigatran etexilate).

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Hospitals  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.